NCT00204529View on ClinicalTrials.gov

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

PHASE3CompletedINTERVENTIONAL
Enrollment

901

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

May 31, 2013

Study Completion Date

December 31, 2016

Conditions
Melanoma
Interventions
DRUG

pegylated interferon-alpha-2a

DRUG

interferon-alpha-2a

Trial Locations (1)

72076

Arbeitsgemeinschaft Dermatologische Onkologie, Skin Cancer Program, Department of Dermatology, University of Tübingen, Tübingen

All Listed Sponsors
collaborator

Dermatologic Cooperative Oncology Group

OTHER

lead

University Hospital Tuebingen

OTHER

NCT00204529 - Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB | Biotech Hunter | Biotech Hunter